An Augmented Reality Audio-Motor Training Game for Improving Speech-in-Noise Perception: Single-Arm Pilot Feasibility Study
HIV and Substance Use Reduction for Youth Experiencing Homelessness: Development and Usability Study
Background: Youth experiencing homelessness face heightened vulnerability to HIV infection and substance use due to complex structural, psychosocial, and behavioral factors. Despite increased mobile phone access among youth experiencing homelessness, few mobile health interventions have been tailored to their unique needs, and even fewer have applied behavioral theory to inform message development. Objective: This study aimed to develop and refine theory-driven, tailored HIV prevention and substance use reduction messages for use in a just-in-time adaptive intervention app, MY-RIDE (Motivating Youth to Reduce Infections, Disconnections, and Emotional dysregulation), designed for youth experiencing homelessness aged 18 to 25 years. Methods: This study was conducted in 4 phases: prevention messages were developed and pilot-tested in 2018 (phase 1), revised and expanded using the experience and expertise of content experts and the study team (phase 2), reviewed for relevance and acceptability by youth experiencing homelessness in 2024 (phase 3), and supplemented with messages generated using an artificial intelligence (AI) tool (phase 4). Results: Phase 1 resulted in the development of 386 intervention messages across 7 content categories: sex urge, drug and alcohol urge, stress, drug use, recent sexual activity, recent sexual assault, and general motivational messages. During phase 2, the study team expanded the message library to 888 messages across 10 categories. During phase 3, the youth working group liked 93% (803/864) of messages reviewed, which were categorized as acceptable for the intervention. Disliked messages were discarded and replaced with messages generated by an AI tool in phase 4. Conclusions: The finalized set of intervention messages was integrated into the MY-RIDE app to support personalized, real-time intervention delivery. Codeveloping messages with youth experiencing homelessness and leveraging AI tools proved feasible and effective for tailoring HIV prevention and substance use content. This approach supports scalable mobile health interventions for marginalized populations and informs future efforts to design engaging, theory-based digital health strategies. A randomized controlled trial of the MY-RIDE intervention is underway. Trial Registration: ClinicalTrials.gov NCT06074354; https://clinicaltrials.gov/study/NCT06074354
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/208f95311fd98302ac027b16dfaa743a" />
Methodological Framework for the Design and Implementation of a US Latine-Hispanic Digital Brain Health Program: User-Centered Design Approach
Background: US Latine and Hispanic communities face a 1.5 times greater risk of developing Alzheimer disease and related dementia (ADRD) with limited access to culturally and linguistically congruent primary prevention education. The COVID-19 pandemic exacerbated the digital divide, highlighting a need to focus on alternative digital methods for delivering brain health and ADRD primary prevention education. Social media emerged as a promising tool. Objective: The objective of this paper is two-fold. We first describe the development and pilot study of our social media–based Latine-Hispanic Digital Brain Health Program guided by evidence-based frameworks in ADRD. We then present the quantitative and qualitative results from the first 14 months of the program (October 2023-December 2024). Methods: We used human-centered design to develop the Digital Alzheimer Health Education Model, which was implemented via 3 social media platforms—Facebook, Instagram, and X (formerly known as Twitter). Our bilingual and bicultural team implemented the model by creating and disseminating tailored educational content in English and Spanish for the resulting Latine-Hispanic Digital Brain Health Program, emphasizing consistency and rapport, storytelling, cultural relevance, linguistic inclusivity, and visual representation. A mixed methods analysis (descriptive statistics and sentiment analysis) was conducted using social media data analytics and users’ comments to guide program evaluation and refinement. Results: From October 2023 to December 2024, we retained 857 followers across our social media platforms (Instagram: n=534; Facebook: n=124; and X: n=199). Growth in follows, consistent reach and engagement, and positive sentiment were observed on Facebook and Instagram. X was not included in the analysis due to data access limitations. Conclusions: The development and pilot study of the Latine-Hispanic Digital Brain Health Program have demonstrated potential in leveraging social media to disseminate brain health and ADRD prevention education to the US Latine and Hispanic communities in English and Spanish. Our preliminary findings demonstrate that culturally and linguistically congruent social media–based approaches hold potential to improve engagement with brain health and ADRD primary prevention education among US Latine and Hispanic populations.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/4b3faccaa5e51c513af4d239916044cb" />
AI in Healthcare: Symposium Insights
For years, artificial intelligence (AI) has been growing behind the scenes of our lives. Starting off as modifications of not‑so‑simple algorithms, early large language models could barely string a few words together, much like early vision systems that struggled to distinguish a lamppost from a cat in digital images. More recently AI has not just grown but proliferated—like Darwin’s finches in the Galapagos—into nearly every niche available in the digital world.
AI has infiltrated into daily life personally and professionally for many, and while modern healthcare has historically been hesitant to adapt to new technologies, Raghav Mani, director of Digital Health at Nvidia, pointed out that healthcare is adopting AI at three times the rate of other industries. Clearly, there is a lot to discuss, which is why The New York Academy of Sciences and the Windreich Department of Artificial Intelligence and Human Health at the Icahn School of Medicine at Mount Sinai co-hosted the 3rd annual “New Wave of AI in Healthcare,” a two-day symposium on May 12 and 13 with the goal of opening discourse between researchers, clinicians, industry leaders and other interested parties on all topics related to AI and healthcare.
Day one
The first day opened with a lightning round of welcome remarks from organizers expressing their personal experience with AI in healthcare research and practice. While some, like Nicholas Dirks, PhD, president and CEO of The New York Academy of Sciences shared concerns about how to maintain human involvement in AI use, he also expressed awe stating that “The pace of progress is breathtaking.”
Others were more practical in their assessments. Lisa Stump, chief digital information officer at Mount Sinai Health System asserted, “The future is not something we enter, it’s something we create.” Similarly, Brendan G. Carr, MD, CEO, Mount Sinai Health System, described AI as a “new partner” to aid clinicians in synthesizing the vast and growing clinical data. Girish N. Nadkarni, MD, a nephrologist and practicing clinician at Icahn School of Medicine at Mount Sinai summarized the whole event before the first talk even began: “The real question is not IF AI will transform healthcare, but HOW.”
The keynote presentation leading day one’s discussions endeavored to answer that very question. With his talk entitled, “Harnessing the power of Platform Thinking to Transform Healthcare,” John Halamka, MD, president of the Mayo Clinic Platform, spent 30 minutes exploring the power of data while questioning how AI is and should be used to analyze the varied data currently available, but cautioned that this is no simple task when considering the sources of data and potential restrictions on data use. He spoke about practical applications of AI data analysis that have and can be done, including in drug discovery. He also pointed out that AI can fill gaps in the healthcare workforce.
The day continued with four talks exploring different aspects of AI model use in healthcare. Marina Sirota, PhD, professor at the University of California, San Francisco spoke about how clinical data can be used for predictive medicine. Others, including Mani and Jonathan Carlson, PhD, vice president and managing director of Microsoft Heath Futures, discussed how AI agents and models can be used as part of hospital and clinician toolkits at multiple levels—not just as data analysis engines, but also to aid in synthesizing patient data and diagnostic support. Rounding out the discussion, Azra Bihorac, MD, senior associate dean for research at the University of Florida described how AI models need to be validated just like any other tool. She also pointed out that while AI is continuously improving in its ability to assess problems and suggest the next best course of action, human input is vital for collaborative success.

The final talks for day one focused on how AI can be used directly with patient care situations. Following their individual talks on how AI can be integrated into electronic health records (EHR), combining models to develop new insights, or reimagining diagnosis ability to improve diagnostic equity, the final three speakers engaged in a dynamic, and sometimes heated panel discussion. Karen Wong, MD, a physician at Epic, Alexander Fedotov, PhD, director of AI digital precision health at AstraZeneca and Pierre Elias, MD, assistant professor at Columbia University Irving Medical Center each shared their thoughts on how AI will be used in the near future. While they were all in agreement that AI cannot replace clinicians, they also recognized that AI will be a disruptive force, but it’s up to clinicians to take responsibility to use the technology as appropriate but to rely on their intuition and judgement as trained professionals. When opining on the future of AI use in healthcare five years from now, Fedotov stated, “I would still want to see humans at the helm of all the decision maker processes.”
Day two
While the first day laid the foundations for AI use in healthcare spanning bench to bedside, the second day of the symposium included more discussion and criticism of AI on the logistic level.

The day began with a keynote fireside chat between Nadkarni and Dave A. Chokshi, MD, a physician and professor at City University of New York, and former NYC health commissioner. He spoke about his leadership experiences, sharing many anecdotes of his time as a public health advocate and communicator during the COVID-19 pandemic. When questioned on the importance of communication considering the state of healthcare and declining trust of the public—especially with the increased use of AI, which has the potential of adding layers of feelings of abandonment, surveillance, and impersonalization—Chokshi pointed out that “It makes relationships even more important that we know then are.” He stressed that a his job, as a clinician, is to build trust with patients, and make sure that they return for care. While he envisions AI being transformative to healthcare in the next few years, he cautioned that listening and integrating feedback from front line users, clinical staff and patients, will be vital.
The morning continued with talks exploring AI’s use in research and learning in healthcare. Joshua C. Denny, MD, CEO of NIH All of Us Research, delivered a detailed summary of the progress and of the All of Us project. Despite recent funding concerns and cuts, the project scope remains on track, and researchers world-wide are utilizing the data derived from this project and how the project leads are working to establish parameters and modules for researchers to more easily implement AI in their data analysis. Andrew Gruen, PhD, standards lead at MLCommons, then spoke animatedly about the importance of establishing standards and benchmarks for AI use in researcher and healthcare settings. He spoke candidly on the need to not just train AI but to have external evaluation and validation of AI models.

The symposium concluded with multiple discussions on the interactions between AI and humans—not just as a tool, but by viewing the use of AI in the broader scale. Karandeep Singh, MD, executive director for health innovation at the University of California, San Diego explored various opinions of clincians and patients on the use of AI, while pointing out that the use of AI in healthcare settings should be thoughtfully considered before implantation. Meanwhile, Vardit Ravitsky, PhD, president and CEO of The Hastings Center for Bioethics, discussed the ethics behind AI use as a direct to patient setting, specifically as a patient-used chatbot. In a debate following their respective talks, the two delved deeply into the risks associated with AI use, both on the patient side with chatbots and with scribe technologies used by clinicians and patients. They often agreed on the need for transparency in AI usage, but specific AI applications, like uses of AI robots in the home to combat loneliness in the elderly resulted in disagreements.
The final talk presented by Tanzeem Choudhury, PhD, chief of health innovation at Cornell Tech, brought many previously discussed topics together. Her research explores how AI can be used in treatment of mental health, describing how AI can be used in multiple aspects of mental health therapy from recording physiological symptoms with wearables to using chatbots for various functions. She cautioned that while these tools may eventually be transformative, the current state of AI use in mental health is still growing.
The closing remarks by Alexander Charney, MD, PhD, professor at Icahn School of Medicine at Mount Sinai summarized the event well. He shared that throughout the symposium he imagined what clinicians and researchers from 100 years ago and from 100 years in the future would think about the current state of healthcare and about the challenges being faced now with how to incorporate AI. He said, “We aren’t the first group of human beings to deal with powerful technology and figuring out how we’re going to use it to change society.” He hopes that the people from the past would see that we understand and respect the past and learn from it being rigorous in our research and testing, while the people from the future will look on us with pride at our fearless and tenacity in the face of new technology. He hopes that both groups would see that we “tried to do the right thing.” He ended saying that he does see all of that here along with passion and coming together of everyone at the meeting.
The post AI in Healthcare: Symposium Insights appeared first on Inside Precision Medicine.
Makary’s departure and Cassidy’s tenuous Senate seat
This week’s episode of “The Readout LOUD” is all about health politics.
We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he is leaving, which of his policies will stick, and what we know about his acting replacement, Kyle Diamantas.
Decoding Anti–Substance Use Public Service Announcements: Content Analysis Grounded in the Elaboration Likelihood Model and Extended Parallel Process Model
Background: Tobacco, alcohol, and illicit drug use continue to pose substantial public health challenges in China. Although public service announcements (PSAs) are widely used for prevention, little is known about how these messages are constructed or the extent to which they draw on established health communication theories. Objective: This exploratory study aimed to characterize the design features of anti–substance use PSAs in China, assess their use of constructs from the extended parallel process model (EPPM) and the elaboration likelihood model (ELM), and compare patterns across anti–substance use PSAs. Methods: We conducted a content analysis of 89 publicly available anti–substance use PSAs produced in mainland China. Messages were identified via major Chinese video platforms and institutional websites and then screened using predefined eligibility criteria. Variables captured message source, intended audience, framing, substance depiction, cultural appeals, and EPPM and ELM components. Frequencies and proportions were calculated, and tests were used to examine differences by PSA type. To account for multiple comparisons, values were adjusted using the Holm-Bonferroni correction. Results: Most PSAs did not identify a target audience (54/89, 60.7%), and public security departments were the most common sponsors (n=37, 41.2%), while none were sponsored by public health agencies. Theory use was selective: response efficacy (n=63, 70.8%) and perceived severity (n=55, 61.8%) appeared more often than self-efficacy (n=45, 50.6%) and perceived susceptibility (n=34, 38.2%); peripheral cues (n=79, 88.8%) were more common than central route cues (n=16, 18%). Differences across PSA types were observed in sponsorship, message features, and theoretical constructs. After adjustment for multiple comparisons, associations involving sponsoring organizations (public security departments and Chinese media) and perceived susceptibility remained statistically significant (all adjusted =.01). Antidrug PSAs were predominantly associated with public security sponsorship, whereas antialcohol and antitobacco PSAs were more frequently linked to Chinese media sources. Perceived susceptibility cues were more common in antismoking PSAs than in antidrug PSAs, while other differences in framing, substance cues, cultural appeals, and ELM or EPPM constructs were not statistically significant after adjustment. Conclusions: Anti–substance use PSAs in China were characterized by limited audience segmentation and uneven use of theory-based persuasive strategies. Observed differences across alcohol-, tobacco-, and drug-focused messages suggest that PSA design may be shaped not only by partial application of communication theory but also by institutional influences and substance-specific contexts. These findings highlight the need for more context-sensitive and theory-informed approaches to anti–substance use PSA design in China.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/52867fbcfe8e52b0bb8afabe3c0cb874" />
Use of Commercially Available Large Language Models to Generate Information Leaflets on Post–Intensive Care Syndrome: Clinical Utility Assessment
Background: Patients and their families without medical knowledge may find professional health care information difficult to understand. The use of large language models (LLMs) to simplify and translate complex medical content holds promise for improving comprehension while reducing the burden on health care providers tasked with delivering explanations. Objective: This study aims to evaluate the quality of information leaflets generated using commercially available LLMs. Methods: Informational texts on post–intensive care syndrome were generated using 6 different LLMs and 4 prompt designs with varying levels of instructional guidance. Clinical practice guideline documents were uploaded and provided to the models as reference context, reflecting a pragmatic clinical scenario without model tuning or advanced retrieval pipelines. In total, 72 texts were generated (6 models × 4 prompts × 3 outputs). After excluding texts shorter than 500 characters (n=16) and those without explicit mention of post–intensive care syndrome (n=3), 53 texts remained. To enable balanced human evaluation across model-prompt combinations, the longest eligible response from each pair was selected (4 prompts × 4 models; n=16). Following independent expert review by 2 medical specialists, 7 texts were excluded, leaving 9 texts for final analysis. Ten individuals, including health care professionals and nonmedical personnel, assessed the texts using a 10-point Likert scale across multiple quality domains. An LLM-based parallel assessment was also conducted, and scores were compared across models and evaluator groups. Results: In the human evaluation of the selected 9 texts, the generated texts achieved an average score of 6.8 or higher across all evaluation criteria, with no potentially harmful content identified. The text generated by LLaMA 3 70B, using a step-by-step approach combined with text-augmented prompting based on clinical guidelines, received the highest overall score, whereas the lowest-rated text was produced using a simple prompt without text augmentation. Although no consistent trends were observed across LLMs or prompt engineering strategies, text-augmented prompting was generally associated with higher evaluation scores. Ratings differed between professional and nonprofessional evaluators. Given the feasibility-driven screening process and the resulting limited sample size, the findings should be interpreted as exploratory and descriptive rather than definitive estimates of overall model performance. Conclusions: Among the selected texts included in the final human evaluation, informational materials generated using commercially available LLMs were generally rated as acceptable by human evaluators, and none contained harmful content. These findings suggest that LLMs may support the development of patient-facing informational materials under feasibility-constrained conditions, although further validation with larger and more diverse samples is warranted.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/2ea53e5bb03a40b2559808dc17a3b7e3" />

